Metastatic sites of baseline as predictors in recurrent or metastatic nasopharyngeal carinoma treated with PD-L1 inhibitor: a secondary analysis of multicenter, single-arm, phase II study (KL-A167)

Metastatic sites of baseline as predictors in recurrent or metastatic nasopharyngeal carinoma treated with PD-L1 inhibitor: a secondary analysis of multicenter, single-arm, phase II study (KL-A167)

Abstract Background Immune checkpoint inhibitors (ICIs) show optimal treatment effects on recurrent or metastatic nasopharyngeal carcinoma(R/M NPC). Nonetheless, whether metastatic sites impact ICIs efficacy remains unclear. Methods We performed a secondary analysis of R/M NPC patients treated with...

Full description

Bibliographic Details
Main Authors: Yuantai Li, Yu Min, Zhigong Wei, Zheran Liu, Yiyan Pei, Yujie Yang, Kun Gao, Ge Song, Shihong Xu, Shuangshuang He, Junyou Ge, Yan Qing, Youneng Wei, Ping Ai, Ye Chen, Xingchen Peng
Format: Article
Language:English
Published: Springer 2025-01-01
Series:Cancer Immunology, Immunotherapy
Subjects:
Metastatic sites
Nasopharyngeal carcinoma
Anti-PD-L1
Survival
Online Access:https://doi.org/10.1007/s00262-024-03905-0

Internet

https://doi.org/10.1007/s00262-024-03905-0

Similar Items